November 23, 2009: Pfizer Jury Awards $28 Million Over Hormone Drugs

By Sophia Pearson

Nov. 23 (Bloomberg) — Two Pfizer Inc. units were ordered to pay a total of $28 million in punitive damages to an Illinois woman who developed breast cancer after taking the companies’ menopause drugs.

Wyeth should pay $16 million and Pharmacia & Upjohn $12 million to Donna Kendall of Decatur, Illinois, a state-court jury in Philadelphia said today. The jury ruled Nov. 20 that the units owed Kendall $6.3 million in compensatory damages.

The verdict brings to more than $165 million the total awarded in cases linking hormone-replacement drugs and breast cancer since they began going to trial in 2006. More than 6 million women have taken the medicines to treat menopause symptoms including hot flashes, night sweats and mood swings.

“Neither the awards of punitive damages nor the liability verdicts were supported by the evidence or the law,” Pfizer spokesman Christopher Loder said in a phone interview. “We plan to challenge both decisions in post-trial motions and, if necessary, through an appeal.”

Until 1995, many patients combined Premarin, Wyeth’s estrogen-based drug, with progestin-laden Provera, made by Upjohn. Wyeth combined the two hormones in Prempro. The drugs are still on the market.

New York-based Pfizer, the world’s largest drugmaker, completed the $68 billion purchase of Wyeth on Oct. 15. The company reported 2008 net income of $8.1 billion on sales of $48.3 billion.

Pfizer rose 26 cents to $18.62 at 2:32 p.m. in New York Stock Exchange composite trading.

The case is Kendall v. Wyeth Pharmaceuticals Inc., 040600965, Court of Common Pleas, Philadelphia County, Pennsylvania. 

Read the full article

Dear Friends and Clients,

In furtherance of our firm’s culture of commitment to always act with compassion, concern and commitment to our clients, community and colleagues, we have been taking precautions to ensure that we are still fulfilling our ethical and moral obligations while prioritizing health, wellness and safety of all we can.

As you know, the COVID-19 pandemic has introduced changes to many lives and businesses in our communities, and around the world. We, much like our neighbors and friends, have been taking precautions to ensure that we are still fulfilling our ethical and moral obligation to our clients, while also prioritizing the health, wellness and safety of our employees.

Until further notice, our offices will be closed to the public to encourage social distancing and to help prevent the spread of COVID-19. Our team is still hard at work, many from home, and you may still call, email, live chat or video conference us if you or a loved one is seeking legal assistance. As the first law firm to offer our clients secure online access to their case file more than a decade ago, we have always been believers in using technology to make life easier and information more accessible. In these present times it has been a smooth transition for us to continue to offer our clients the same seamless and thorough service that you deserve and are accustomed to.

This pandemic is unlike anything any of us have faced in our lifetimes, and while we can continue to emotionally support one another through it all, staying home and keeping your distance is vital to the health and wellness of our communities. It does not feel good to break routines, cancel events and retreat from our normal, day-to-day socializing, but let us remember that, in times of strife, prior generations were asked to go to war and we are simply being asked to stay home. Your isolation equals more lives saved, and more time for medical providers to prepare for the treatment of patients battling COVID-19.

When the dust settles, we will join together with a greater appreciation for our lives, local businesses, loved ones and health. Until then, we will continue to offer guidance from a safe distance.

Very truly yours,

Andrew G. Finkelstein and the staff of Finkelstein & Partners, LLP